Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.

Welch S, Spithoff K, Rumble RB, Maroun J; Gastrointestinal Cancer Disease Site Group.

Ann Oncol. 2010 Jun;21(6):1152-62. doi: 10.1093/annonc/mdp533. Epub 2009 Nov 25. Review.

PMID:
19942597
2.

Anti-angiogenic therapies for metastatic colorectal cancer.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Review.

PMID:
19588372
3.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
5.

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.

Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z.

Int J Colorectal Dis. 2009 Jun;24(6):677-85. doi: 10.1007/s00384-009-0655-9. Epub 2009 Jan 30.

PMID:
19184059
6.
7.

A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.

Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, Yang YP, Xu YQ, Lv SW, Zhu YL.

Indian J Cancer. 2014 Mar;51 Suppl 3:e95-8. doi: 10.4103/0019-509X.154084.

8.

Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.

Li J, Zhou L, Chen X, Ba Y.

Clin Transl Oncol. 2015 Sep;17(9):673-83. doi: 10.1007/s12094-015-1293-z. Epub 2015 May 20. Review.

PMID:
25990506
9.

Managing patients with metastatic colorectal cancer on bevacizumab.

Lemmens L, Claes V, Uzzell M.

Br J Nurs. 2008 Aug 14-Sep 10;17(15):944-9. Review.

PMID:
18983014
10.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
11.

FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S.

Clin Colorectal Cancer. 2013 Sep;12(3):145-51. doi: 10.1016/j.clcc.2013.04.006. Epub 2013 Jun 10. Review.

PMID:
23763824
13.

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

Whyte S, Pandor A, Stevenson M, Rees A.

Health Technol Assess. 2010 Oct;14(Suppl. 2):47-53. doi: 10.3310/hta14suppl2/07. Review.

14.

Optimizing the efficacy of first-line chemotherapy plus bevacizumab in metastatic colorectal cancer: analysis of multiple methods.

Li S, Chi P.

BioDrugs. 2011 Feb 1;25(1):43-50. doi: 10.2165/11584680-000000000-00000.

PMID:
21080747
15.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

16.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
17.

[Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].

Zhang T, Yuan S, Wang Z, Zhang Q, Zhao P, Shan L.

Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):82-90. doi: 10.3779/j.issn.1009-3419.2013.02.05. Chinese.

18.

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.

Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A; Investigators of the BRiTE study.

Oncologist. 2009 Sep;14(9):862-70. doi: 10.1634/theoncologist.2009-0071. Epub 2009 Sep 2.

19.

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.

Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW.

Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11.

PMID:
22782485
20.

The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials.

Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X.

Cancer Biother Radiopharm. 2013 Sep;28(7):501-9. doi: 10.1089/cbr.2012.1458. Epub 2013 Jun 15. Review.

Supplemental Content

Support Center